Financials data is unavailable for this security.
View more
Year on year Divi's Laboratories Ltd 's net income deteriorated -12.25% from 18.23bn to 16.00bn despite relatively flat revenues. A contributing factor has been the increase in the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percent of sales).
| Gross margin | 59.91% |
|---|---|
| Net profit margin | 21.31% |
| Operating margin | 25.24% |
| Return on assets | 12.29% |
|---|---|
| Return on equity | 13.91% |
| Return on investment | 13.32% |
More ▼
Cash flow in INRView more
In 2024, Divi's Laboratories Ltd increased its cash reserves by 113.53%, or 1.93bn. The company earned 12.61bn from its operations for a Cash Flow Margin of 16.07%. In addition the company used 2.69bn on investing activities and also paid 7.99bn in financing cash flows.
| Cash flow per share | 83.69 |
|---|---|
| Price/Cash flow per share | 70.50 |
| Book value per share | 516.71 |
|---|---|
| Tangible book value per share | 516.56 |
More ▼
Balance sheet in INRView more
| Current ratio | 7.24 |
|---|---|
| Quick ratio | 4.80 |
| Total debt/total equity | 0.0006 |
|---|---|
| Total debt/total capital | 0.0006 |
More ▼
Growth rates in INR
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -12.25%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.77% |
|---|---|
| Div growth rate (5 year) | 13.40% |
| Payout ratio (TTM) | 43.36% |
| EPS growth(5 years) | 3.41 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 37.82 |
More ▼
